Type to search

Daniel O’Day

Share
Daniel O'Day
Chairman and Chief Executive Officer
Gilead Sciences

Daniel O'Day

Working with Gilead’s 13,000 employees worldwide to create new possibilities in medicine. Delivering on our long term commitment to groundbreaking science and access so we can help make the world a better, healthier place.

Posts Featuring Daniel O’Day


Warning: Illegal string offset 'ID' in /home/customer/www/pharmtechfocus.com/public_html/wp-content/themes/magplus-child/single-people.php on line 101

Warning: Illegal string offset 'ID' in /home/customer/www/pharmtechfocus.com/public_html/wp-content/themes/magplus-child/single-people.php on line 101

Warning: Illegal string offset 'ID' in /home/customer/www/pharmtechfocus.com/public_html/wp-content/themes/magplus-child/single-people.php on line 101

Warning: Illegal string offset 'ID' in /home/customer/www/pharmtechfocus.com/public_html/wp-content/themes/magplus-child/single-people.php on line 101

Warning: Illegal string offset 'ID' in /home/customer/www/pharmtechfocus.com/public_html/wp-content/themes/magplus-child/single-people.php on line 101

Warning: Illegal string offset 'ID' in /home/customer/www/pharmtechfocus.com/public_html/wp-content/themes/magplus-child/single-people.php on line 101

Warning: Illegal string offset 'ID' in /home/customer/www/pharmtechfocus.com/public_html/wp-content/themes/magplus-child/single-people.php on line 101

Warning: Illegal string offset 'ID' in /home/customer/www/pharmtechfocus.com/public_html/wp-content/themes/magplus-child/single-people.php on line 101

Warning: addcslashes() expects parameter 1 to be string, array given in /home/customer/www/pharmtechfocus.com/public_html/wp-includes/wp-db.php on line 1539
Gilead Announces First Global Regulatory Approval of Sunlenca® (Lenacapavir), the Only Twice-yearly HIV Treatment Option | Pharmtech Focus

Gilead Announces First Global Regulatory Approval of Sunlenca® (Lenacapavir), the Only Twice-yearly HIV Treatment Option

FDA Approves Veklury® (Remdesivir) for the Treatment of Non-Hospitalized Patients at High Risk for COVID-19 Disease Progression | Pharmtech Focus

FDA Approves Veklury® (Remdesivir) for the Treatment of Non-Hospitalized Patients at High Risk for COVID-19 Disease Progression